The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT ID: NCT00427219

Last Updated: 2021-10-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-23
• Study Completion Date: 2008-02-27

Brief Summary

This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

Detailed Description

This study is to compare the improvement in symptom scores, peak flow rate and quality of life in men suffering from lower urinary tract symptoms (LUTS) secondary to Benign Prostatic Hypertrophy (BPH) following treatment with ozarelix. Ozarelix is compared to placebo and injections given 14 days apart. Patients are followed for 6 months and both safety and efficacy assessed at monthly visits. Additionally, the impact of treatment on erectile function, if any, as well as Prostate-Specific Antigen (PSA) and Testosterone levels will be monitored.

The screening period of 7 days. The duration of the study is 40 weeks, including a 28-day placebo run-in phase (eligible participants entered a placebo run-in phase in which placebo is administered twice over a 2 week period [Day -28 and Day -14] and participants are assessed to establish baseline values approximately 14 days following the second placebo injection), study drug is administered on Days 0 and 14 followed by 34 weeks of observation after the last dose of study drug.

Conditions

Benign Prostatic Hypertrophy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Ozarelix

All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.

Group Type: EXPERIMENTAL

Ozarelix

Intervention Type: DRUG

Ozarelix 15 mg will be administered IM on Day 0 and Day 14.

Placebo

All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo will be administered IM on Day 0 and Day 14.

Interventions

Ozarelix

Ozarelix 15 mg will be administered IM on Day 0 and Day 14.

Intervention Type: DRUG

Placebo

Placebo will be administered IM on Day 0 and Day 14.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• All of the following questions must be answered "Yes" at Visit 1 in order for the participant to participate in the study.

• Is the participant at least 50 years old?
• Does the participant have clinical signs and symptoms consistent with BPH?
• Does the participant have an IPSS 13 at screening (prior to placebo run in)?
• Does the participant have a peak urinary flow rate (Qmax) of 4-15 milliliter/second (mL/sec) established on a voided volume of at least 125 mL?
• Is the participant willing to agree not to use any other approved or experimental pharmacologic BPH treatments including alpha blockers, 5-alpha reductase inhibitors, anti-cholinergic preparations or herbal preparations at any time during the study?

Exclusion Criteria

• Does the participant have a history of prostate cancer or a serum PSA >10 nanograms per milliliter (ng/mL)?
• Has the participant had prior prostate or bladder surgery, pelvic surgery (excluding hernia repair), pelvic radiation or lower urinary tract malignancy?
• Does the participant have a prevoid total bladder volume assessed by ultrasound > 550 mL?
• Does the participant have a residual urine volume > 350 mL by ultrasound?

• Minimum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Spectrum Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Donald Gleason, MD

Tucson, Arizona, United States

Jay Young, MD

Laguna Hills, California, United States

Alexander Gershman, MD

Los Angeles, California, United States

Stephen Auerbach, MD

Newport Beach, California, United States

Eugene Dula, MD

Tarzana, California, United States

Joel Kaufman, MD

Aurora, Colorado, United States

Ira Klimberg, MD

Ocala, Florida, United States

Joseph Williams, MD

Meridian, Idaho, United States

Christopher Steidle, MD

Fort Wayne, Indiana, United States

Steven Bigg, MD

St Louis, Missouri, United States

Jed Kaminetsky, MD

New York, New York, United States

William Fitch, MD

San Antonio, Texas, United States

Gregg Eure, MD

Virginia Beach, Virginia, United States

Countries

United States

Other Identifiers

SPI-153-06-1

Identifier Type: -

Identifier Source: org_study_id